Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities
Net loss	$ (11,440,000)	$ (10,696,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	1,522,000	1,335,000
Common stock issued in lieu of salary to officers and fees for services from vendors	710,000	898,000
Common stock issued for interest	200,000	524,000
Interest expense related to amortization of the discount on convertible notes payable and line of credit and deferred financing costs	3,376,000	2,766,000
Loss on extinguishment of debt	1,029,000	745,000
Debt conversion expense		276,000
Deferred offering expense	53,000	19,000
Financing fee paid in stock (cancellation)	(42,000)	42,000
Warrant reprice	56,000
Amortization and depreciation expense	65,000	50,000
Bad debt expense	24,000
Changes in assets and liabilities:
Accounts receivable	(121,000)	(163,000)
Inventories	9,000	28,000
Accounts payable and accrued expenses	123,000	284,000
Deferred revenue	35,000
Prepaid expenses and other assets	(21,000)	1,000
Net cash used in operating activities	(4,422,000)	(3,891,000)
Cash flows from investing activities
Equipment purchases	(35,000)	(58,000)
Net cash used in investing activities	(35,000)	(58,000)
Cash flows from financing activities
Proceeds from convertible notes payable	1,632,000	705,000
Proceeds from OID offering	2,703,000
Repayment of Clyra Medical note payable		(243,000)
Proceeds from notes payable		400,000
Proceeds from line of credit		430,000
Proceeds from conversion inducement		357,000
Proceeds from warrant buy down		149,000
Proceeds from warrant exercise	560,000
Repayment of note payable	(915,000)
Repayment of letter of credit	(175,000)
Net cash provided by financing activities	4,466,000	3,642,000
Net effect of foreign currency translation	(9,000)	(28,000)
Net change in cash		(335,000)
Cash at beginning of year	655,000	990,000
Cash at end of year	655,000	655,000
Supplemental disclosures of cash flow information
Interest	195,000	54,000
Income taxes	3,000	13,000
Non-cash investing and financing activities
Fair value of warrants issued with convertible notes and letter of credit	3,931,000	795,000
Note payable issued for intellectual property		1,250,000
Liability to Scion Solutions, LLC		643,000
Clyra preferred shares dividend exchange for Clyra common stock	270,000
Right of use / operating lease	411,000
Deemed dividend	809,000	297,000
Conversion of Convertible Notes Payable into Common Stock [Member]
Non-cash investing and financing activities
Conversion of debt	1,735,000	6,190,000
Conversion of Convertible Notes Issued with Original Issue Discount [Member]
Non-cash investing and financing activities
Conversion of debt	1,008,000
Conversion of Convertible Note Payable into Shares of Clyra [Member]
Non-cash investing and financing activities
Conversion of debt	440,000
Stock Issued for Equipment [Member]
Non-cash investing and financing activities
Fair value of stock issued		10,000
Fair value of stock issued		(10,000)
Stock Issued for Financing Fee [Member]
Non-cash investing and financing activities
Fair value of stock issued		85,000
Fair value of stock issued		(85,000)
Stock Issued for Conversion of Clyra Line of Credit [Member]
Non-cash investing and financing activities
Fair value of stock issued		250,000
Fair value of stock issued		(250,000)
Stock Issued for Exercise of Stock Options [Member]
Non-cash investing and financing activities
Fair value of stock issued		12,000
Fair value of stock issued		(12,000)
Clyra Medical Common Stock [Member]
Cash flows from financing activities
Proceeds from the sale of stock	536,000	1,005,000
Lincoin Park Capital Stock [Member]
Cash flows from financing activities
Proceeds from the sale of stock	$ 125,000	$ 839,000